Folate deficiency has often been described both in Crohn’s disease and ulcerative colitis

(Table 1). Decreased dietary intake, increased demands, malabsorption due to mucosal

impairment and sulfasalazine competitive inhibition of folate absorption, are associated with

folate deficiency. Folate deficiency may also be primary or secondary to vitamin B12

deficiency. Besides systemic deficiency, increased intestinal cell turnover due to epithelial

inflammation could also result in folate deficiency in patients with UC. Steger et al.

performed an oral folate absorption test in 100 CD patients and detected abnormal folate

absorption in 25 patients. The abnormal folate absorption test was correlated with disease

extent and activity. Furthermore, no increase of the serum folate levels was detected in 9 out

of 25 patients after oral folate supplementation [38]. Koutroubakis et al. reported that serum

folate levels were significantly lower in both CD and UC patients than in controls [21]. Zezos

et al. investigated the folate, vitamin B12 and homocysteine status in 40 UC patients and

identified 3 (7.5%) cases with low serum folate levels [39]. High prevalence (20-80%) of

folate deficiency in IBD patients is reported in data from 70’s and 80’s [11,40-43]. On the

contrary, in recent studies the prevalence of folate deficiency was low or even absent in IBD

patients, although serum folate levels were lower in IBD patients compared to healthy

controls [19,21,22]. One possible explanation for this discrepancy on data is the modification

of dietary folate intake in the recent years in the general population or the more frequent use

of vitamin supplements, including IBD patients. Furthermore, nowadays sulfasalazine has

been replaced by mesalazine, a drug that does not interfere with folate absorption, although a

correlation between intake of sulfasalazine and low folate levels has not been constantly

found in IBD patients [12,42]

64 Petros Zezos and Georgios Kouklakis

3. Clinical Consequences of Vitamin B Complex Deficiencies in IBD

Patients

The “vitamin B complex” deficiencies are implicated in a wide array of clinical

manifestations or complications in patients with IBD. Macrocytic anemia is associated with

folate and vitamin B12 deficiency. Deficiencies of folate, vitamin B12 and vitamin B6 can

cause hyperhomocysteinemia, an independent risk factor for both venous and arterial

thrombosis. Furthermore, low folate status has been associated with increased risk of

adenoma or colorectal cancer development in the general population and in individuals with

ulcerative colitis. Finally, there have been some rare cases reporting clinical syndromes

related to specific deficiencies of water-soluble B vitamins (pellagra, beriberi).

Megaloblastic Anemia in IBD Patients

Iron deficiency and anemia of chronic disease are the most common causes of anemia in

IBD patients [44]. Megaloblastic anemia due to folate or vitamin B12 deficiency is a less

frequent cause of anemia in IBD patients. The vitamin B12 is stored in the liver (~5 mg) and

has a low turnover rate with small daily requirements. In patients with inflammatory bowel

disease, ileal disease disrupting the enterohepatic circulation leads t greater losses of vitamin

B12 than that of a vegetarian not ingesting any vitamin B12. Thus, vitamin B12 deficiency

would occur in these patients in only a few years. Clinical evidence of vitamin B12 deficiency

occurs late as body stores have to be depleted to less than 10%. Vitamin B12 deficiency seems

to be common in patients with ileal CD or resection of the ileum, but its haematopoietic

consequence in CD is unclear. In general, folate deficiency seems to be more common than

vitamin B12 deficiency. Clinical manifestations of folate deficiency occur earlier as folate

stores last only 1-2 months.

In a recent study, Lakatos et al. [44] reported that the prevalence of macrocytic anemia

was 4.3% in CD patients and 4.9% in UC patients, but unfortunately without distinguishing

between folate and vitamin B12 deficiency. Overall, the percentages of macrocytic anemia

among anemic IBD patients were 7.3% in CD patients and 9.2% in UC patients.

Although folate and vitamin B12 deficiencies occur often in IBD patients the

manifestations of symptomatic deficiency (hematological and neurological consequences),

are not usually present. Several studies have observed a discrepancy between the measured

serum concentration of vitamin B12 and true deficiency as confirmed by Schilling test and

methylmalonic acid concentration. Methylmalonic acid accumulates in vitamin B12

deficiency and is specific for vitamin B12 deficiency state [45,46]. One possible explanation is

that in malnutrition states the carrier proteins in the serum are depleted before tissue levels

fall enough to produce symptoms of deficiency, and therefore serum levels of vitamin B12 do

not reflect true body stores. In general, red blood cell folate levels are considered as a better

indicator of tissue stores (intermediate-term stores) than serum folate levels (short-term

stores), and are less susceptible to rapid changes in diet [47,48]. Since most of the studies

have evaluated the serum folate status in IBD patients, it is possible that the folate deficiency

reported is not severe enough (depletion of tissue stores) to produce clinically evident

macrocytic anemia. On the other hand, some investigators suggest that serum folate

Nutritional Issues in Inflammatory Bowel Disease… 65

measurements provide equivalent information to red cell folate measurements about folate

status [49].

Hyperhomocysteinemia and Thromboembolic Disease in IBD Patients

The risk for thromboembolic complications is increased in patients with inflammatory

bowel disease. The incidence of arterial and venous thromboembolic disease in patients with

ulcerative colitis and Crohn’s disease has been reported between 1% and 8% [50,51], rising

to an incidence of 39% in some autopsy studies [52]. Several studies have shown that a

hypercoagulable state involving all components of clotting system exists in IBD [53-55]. This

hypercoagulable state may be related to an increased tendency for thromboembolic events

and may be linked to the disease pathogenesis through promoting microthrombi formation in

the intestinal microcirculation [56,57]. The aetiology and pathogenesis of the

hypercoagulable state in IBD have not been fully elucidated but may be induced through a

procoagulant effect of proinflammatory cytokines [58-62] in combination with acquired or

genetic defects of clotting factors (protein S, protein C, antithrombin, factor V Leiden,

prothrombin mutation 20210A, antiphospholipid antibodies) [63-65].

Homocysteine (Hcys) is a non-essential, sulfur-containing amino acid formed during the

metabolism of methionine (Figure 1). The first step in the synthesis of homocysteine is the

formation of S-adenosylmethionine (SAM, AdoMet), an important methyl donor, from

methionine. AdoMet is then converted to S-adenosylhomocysteine (AdoHcy), which is

further hydrolyzed to yield homocysteine and adenosine. Depending on whether there is a

relative excess or a deficiency of methionine, homocysteine may then enter either

transsulfuration or remethylation pathways. If methionine stores are adequate, homocysteine

enters the transsulfuration pathway, where it is converted to cysteine in a series of reactions

catalyzed by the vitamin B6 -dependent enzymes cystathionine beta-synthase (CBS) and

gamma-cystathionase. If methionine conservation is necessary, homocysteine enters a

remethylation pathway. Remethylation may occur by one of two reactions. In one,

homocysteine is reconverted to methionine by transfer of a methyl group from 5-

methyltetrahydrofolate in a reaction catalyzed by cobalamin (vitamin B12)-dependent

methionine synthase (MS). The formation of 5-methyltetrahydrofolate is catalyzed by

methylenetetrahydrofolate reductase (MTHFR), which requires vitamin B2 (riboflavin) as a

cofactor. The other remethylation pathway operates independently of vitamin B12 and folate

but uses betaine as a methyl donor and requires betaine-homocysteine methyltransferase

(BHMT). Abnormalities of these pathways, as a result of nutrient deficiencies or enzyme

inactivity, may result in the accumulation of homocysteine.

Mild hyperhomocysteinemia (hHcys), which occurs in approximately 5-7% of the

general population, has been proved to be thrombogenic and an independent risk factor for

coronary artery disease [66], arterial and venous thrombosis [67-72]. Elevated levels of Hcys

may result from abnormalities in metabolism pathways due to inherited abnormalities of the

enzymes involved or nutrient deficiencies such as insufficiency of folate and vitamins B2, B6

and B12 [73-74].

66 Petros Zezos and Georgios Kouklakis

Figure 1. Metabolic pathways of homocysteine.

The mechanism by which hyperhomocysteinemia promotes thrombosis is uncertain, but

it may be related to promoting a hypercoagulate state due to endothelial dysfunction [74-76].

Vitamin B12 and folate deficiency are relatively common conditions in IBD (especially in

active disease) through malnutrition, malabsorption or antifolate drugs such as methotrexate

and sulfasalazine. Deficiencies of key nutrients/cofactors in Hcys metabolism pathways (B2,

B6, B12, and folate) might lead to raised Hcys levels in IBD.

The association between IBD and hyperhomocysteinemia (hHcys) has been shown in

many recent studies, reporting an increased prevalence of hHcys in IBD (both UC and CD)

[17,19,21,22,39,77-81]. In most of these studies low serum folate level (and, to a lesser

extent, a low serum vitamin B12 level) was a strong independent risk factor for

hyperhomocysteinemia. Koutroubakis et al [21], Zezos et al. [39], Chowers et al. [19], and

Papa et al. [80] reported elevated homocysteine levels related to low serum folate status in

IBD patients. On the other hand, Romagnuolo et al. [79] reported an inverse correlation

between serum homocysteine levels and serum vitamin B12 levels. Furthermore, Saibeni et al.

[17] in their study underscored the relationship between low vitamin B6 plasma levels and

hyperhomocysteinemia in IBD patients. Moreover, Oldenburg et al. [78] found that

hyperhomocysteinemia correlated with serum folate, vitamin B12 and vitamin B6 status in

IBD patients. On the contrary, Drzewoski et al. [81] stated that elevated homocysteine levels

in UC patients correlated with disease activity and duration, and not with folate and vitamin

B12 deficiency.

Nutritional Issues in Inflammatory Bowel Disease… 67

Thromboembolic disease is a serious extraintestinal manifestation of inflammatory bowel

disease (IBD), causing significant morbidity and mortality in IBD patients. Thrombosis

occurs more often in the deep veins of the legs and the pulmonary circulation; however,

arterial thrombotic complications and numerous other less frequent sites of venous

thrombosis have also been described: cerebrovascular disease, internal carotid artery

occlusion, portal vein thrombosis, Budd-Chiari syndrome, cutaneous gangrene secondary to

microvascular thrombosis, retinal vein occlusion, ischaemic heart disease.

Hyperhomocysteinemia has been reported in the test results in cases of thromboembolic

complications in IBD patients. In our study [39], folate deficiency-related

hyperhomocysteinemia was found in one UC patient with severe cerebrovascular accident.

Gonera et al. reported cerebral venous thrombosis and deep vein thrombosis associated with

mild hyperhomocysteinemia in a 30-year-old woman with recently diagnosed ulcerative

colitis [82]. Slot et al. [83], described a case of folate deficiency-related

hyperhomocysteinemia in a 33-year-old woman with Crohn’s disease who presented with

ischemic spinal cord injury due to thrombosis of the distal aorta during a relapse of the

disease. Moreover, in another case [84] severe massive pulmonary embolism was described

in a young man with ulcerative colitis and laboratory investigation revealed

hyperhomocysteinemia due to folate and vitamin B12 deficiency. In addition, Younes-Mheni

et al. [85], reported a case of large-artery stroke in a 39-year-old woman with Crohn’s disease

due to vitamin B6 deficiency-induced hyperhomocysteinemia. Finally, Kao et al. [86]

described 4 pediatric patients with ulcerative colitis and cerebral sinovenous thrombosis.

Increased homocysteine levels were found in one patient.

Recently, Papa et al. [87] reported that elevated serum homocysteine was an important

factor associated with increased intima-media thickness of the wall of the common carotid

artery in IBD patients.

Increased homocysteine levels have also been observed in colonic mucosa of patients

with inflammatory bowel disease [88]. In a recent study, Danese et al. [89] observed

increased levels of homocysteine both in plasma and intestinal mucosa in IBD patients.

Increased levels of homocysteine contributed to mucosal microvascular inflammation through

activation of the endothelium.

Studies indicate that 20% of dietary methionine is metabolized in the gastrointestinal

tract. The gastrointestinal tract accounts for ~25% of whole body transmethylation and

transsulfuration and is a site of homocysteine release to the systemic circulation. It is possible

that a fraction of the increased circulating homocysteine levels in IBD patients may be due to

increased intestinal synthesis [90]. Further studies are needed to investigate the association

between the serum and mucosal homocysteine, the folate status and the inflammatory injury

in patients with inflammatory bowel disease.

Folate and Colorectal Carcinogenesis in IBD Patients

Research data from the past decade provided evidence that folate status may be involved

with the development and prevention of several malignancies, including cancer of the

colorectum, lungs, pancreas, esophagus, stomach, cervix, and breast, as well as

neuroblastoma and leukemia [91,92]. Overall, research data suggest an inverse association

68 Petros Zezos and Georgios Kouklakis

between folate status and the risk of these malignancies [91,92]. The role of folate in

carcinogenesis has been best studied for colorectal cancer [92-95].

Folate and Ulcerative Colitis-Associated Colorectal Carcinogenesis

Patients with chronic ulcerative colitis have a grater risk of developing colorectal cancer

than the general population [96]. In a recent meta-analysis of all published studies reporting

the colorectal cancer risk in ulcerative colitis patients, Eaden et al. reported that the risk for

any patient with ulcerative colitis is 2% at 10 years, 8% at 20 years, and 18% after 30 years

of disease [97]. Increased extent and longer duration of the disease are known risk factors for

the development of dysplasia and colorectal cancer in UC patients [98-100].

Epidemiological data have shown an inverse relationship between dietary folate intake

and sporadic colorectal cancer [101-103]. Although there is no direct evidence to link any

dietary factor and cancer risk, folate deficiency, which is common in UC patients, may be

implicated in the development of dysplasia and colorectal cancer in these patients. Lashner et

al. [104] first reported that individuals with long-standing ulcerative colitis and taking folate

supplementation had 62% lower incidence of colorectal dysplasia and cancer compared with

those not receiving folate supplementation. In another study by Lashner et al., the risk of

colorectal dysplasia and cancer was found to be significantly decreased by 18% for each 10

ng/ml increase in red blood cell folate concentrations in patients with ulcerative colitis [105].

Moreover, in a recent study, folic acid supplementation had an inverse dose-dependent

relationship with the risk of colorectal neoplasia in subjects with longstanding ulcerative

colitis [106]. These studies suggest an inverse relationship between folate status and the risk

of ulcerative colitis-associated colorectal cancer. There are currently no placebo-controlled

studies of folate supplementation in the prevention of ulcerative colitis-associated cancer.

Studies with animal models of colorectal dysplasia and cancer associated with ulcerative

colitis (interleukin-2 and β2- microglobulin deficient mouse) [107-110], have shown that

dietary folate supplementation at four times the basal dietary requirement significantly

suppresses colorectal carcinogenesis associated with ulcerative colitis in this model [107].

Carcinogenic Effects of Folate Deficiency

Folate is an essential cofactor for purine and pyrimidine metabolism and plays and

important role in DNA synthesis and cellular proliferation (Figure 2). Folate is also a critical

factor for DNA methylation (Figure 2), which is important epigenetic determinant in gene

expression, in the maintenance of DNA integrity and stability, in chromosomal modifications

and in the development of mutations. [91,92,111-115].

Accumulating evidence from in vitro, animal and human studies indicates that folate

deficiency is associated with DNA damage though many mechanisms (DNA strand breaks,

impaired DNA repair, altered DNA methylation and increased mutations) (Table 3), that

contribute to colorectal cancer development, and that folate supplementation can correct

some of these folate deficiency-induced defects [91,92,111-115].

Nutritional Issues in Inflammatory Bowel Disease… 69

Figure 2. Folate metabolic cycle involving DNA synthesis and methylation.

Table 3. Potential mechanisms of the folate deficiency-mediated colorectal cancer

development

1. Aberrant genomic and site specific DNA methylation

 Deactivation of tumor suppressor genes

2. Altered DNA methylation (hypomethylation) and cellular proliferation

 Increased gene expression

 DNA strand breaks, acquisition of mutations

 Proto-oncogene activation

3. DNA damage, nucleotide pool imbalance (uracil misincorporation)

4. Increased mutagenesis

5. Abnormal apoptosis

6. MTHFR polymorphisms ( thermolabile variant C677T) and related gene-nutrient

interactions

Impact of other Micronutrients in Colorectal Neoplasia

Some other members of the “vitamin B complex”, that participate in folate metabolism

play also role in DNA stability. The vitamin B12 is a cofactor for methionine synthase and

hence is a critical modulator of cellular methylation status. Riboflavin is also an important

cofactor for the MTHFR enzyme (Figure 2). Recently it has been demonstrated that

riboflavin binds with lower affinity to the MTHFR thermolabile variant (TT variant, C677T

mutation) and that riboflavin deficiency further impairs the functioning of this enzyme

[116,117]. Therefore, low riboflavin levels might accentuate the metabolic defect in MTHFR

thermolabile variant carriers, whereas high riboflavin levels might minimize the defect.

70 Petros Zezos and Georgios Kouklakis

The vitamin B12 and riboflavin levels were not measured in the majority of studies and

therefore their impact on the risk of developing colorectal cancer cannot be estimated. Future

studies in this area will have to address both the genetic and micronutrient factors (folate,

ideally colonic epithelial levels, vitamin B12, and methionine levels among others) involved

in folate metabolism to unravel the relative importance of each element.

A number of studies have suggested an increased risk of colorectal cancer in patients

with Crohn’s colitis [118,119,120], but few data exist about the factors that increase the risk

of dysplasia and colorectal cancer in Crohn’s colitis patients [121-125]. Although the risk of

colorectal neoplasia appears to be of the same magnitude in UC and Crohn’s colitis and the

“vitamin B complex” deficiencies are frequent in both diseases, we found no data about the

role of folate and the other members of the “vitamin B complex” in colorectal cancer

development in patients with Crohn’s disease affecting the colon. Future studies concerning

with the role of nutritional factors in colorectal neoplasia development should include

patients with Crohn’s colitis.

Clinical Syndromes Related to Deficiencies of the other Members of the

“Vitamin B Complex” (Except Folate and B12)

There are some rare cases in the literature reporting syndromes due to deficiencies of

water-soluble B vitamins in IBD patients, resembling beriberi (thiamine) [126], pellagra

(nicotinic acid) [127,128], or photophobia with dermatological changes (riboflavin) [129-

130].

 

In: Vitamin B: New Research ISBN 978-1-60021-782-1

Editor: Charlyn M. Elliot, pp. 57-80 © 2008 Nova Science Publishers, Inc.

Chapter IV

NUTRITIONAL ISSUES IN

INFLAMMATORY BOWEL DISEASE: FOCUS ON

THE VITAMIN B COMPLEX DEFICIENCIES AND

THEIR CLINICAL IMPACT

Petros Zezos1,∗ and Georgios Kouklakis2

1

Gastroenterology & Hepatology Department, Military General Hospital of

Alexandroupolis, Alexandroupolis, Greece;

2

Endoscopy Unit, University General Hospital of Alexandroupolis, Democritus

University of Thrace, Alexandroupolis, Greece.

ABSTRACT

Inflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammatory

condition of unknown cause, which manifests with two major forms: as Crohn’s disease

(CD), affecting any part of the gastrointestinal tract and as ulcerative colitis (UC),

affecting the colon. Medical management with aminosalicylates (5-ASA), steroids, and

immunomodulating or immunosuppressive agents is the mainstay of therapy for most

IBD patients. Surgery is reserved for patients with severe disease refractory to medical

management or for patients with complications.

Nutrition plays an important role in pathogenesis, management and treatment of

IBD. Malnutrition is a common problem in patients with IBD, especially in those

suffering from Crohn’s disease (CD). A wide array of vitamin and mineral deficiencies

has been described in patients with IBD. Nutritional abnormalities are often overlooked

in the management of IBD patients, despite their pathogenic role in clinical

manifestations and complications of IBD. The causes of malnutrition in IBD are

multiple, including decreased oral nutrient intake, malabsorption, excessive nutrient

losses, increased nutrient requirements, and iatrogenic due to surgery or medications.

∗

 Correspondence concerning this article should be addressed to: Petros Zezos, MD, 40 Venizelou Str., 68100

Alexandroupolis, Greece. Tel.: +30-25510-84166; Fax: +30-25510-84168; Email: zezosp@hol.gr.

58 Petros Zezos and Georgios Kouklakis

Thiamin (B1), riboflavin (B2), niacin, pyridoxine (B6), pantothenic acid, biotin, folic

acid (B9) and vitamin B12 are referred to as members of the “vitamin B complex”. These

are water-soluble factors, playing an essential role in the metabolic processes of living

cells, functioning as coenzymes or as prosthetic groups bound to apoenzymes. These

vitamins are closely interrelated and impaired intake of one may impair the utilization of

others.

Folate and vitamin B12 deficiencies are frequently described in IBD patients and are

implicated in anemia, thrombophilia and carcinogenesis associated with IBD. Low serum

concentrations of other members of the “vitamin B complex” have also been described in

IBD patients, producing the syndromes due to their deficiency.

This article focuses on the recent research for the aetiology, the clinical

consequences and the management of the vitamin B complex deficiencies in patients with

inflammatory bowel disease.

Keywords: Aetiology; Crohn’s disease; complications; inflammatory bowel disease; therapy;

ulcerative colitis; vitamin B complex.

INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammatory

process, which manifests with two major forms: as Crohn’s disease (CD), affecting any part

of the gastrointestinal tract and as ulcerative colitis (UC), affecting the colon. The aetiology

and pathogenesis of IBD are still unclear. Medical management with aminosalicylates (5-

ASA), steroids, and immunomodulating or immuno-suppressive agents is the mainstay of

therapy for most IBD patients, while surgery is reserved for patients with severe disease

refractory to medical management or for patients with disease complications.

Nutrition plays an important role in IBD pathogenesis, management and treatment. The

epidemiological observation that populations with different dietary habits may have different

incidences of IBD suggests that some nutrients may play a pathogenic role in the disease

process. On the other hand, malnutrition is a common problem in patients with established

IBD, especially in those suffering from Crohn’s disease (CD). Besides protein-energy

malnutrition, a wide array of vitamin and mineral deficiencies has been described in patients

with IBD. Nutritional abnormalities are often overlooked in the management of IBD patients,

despite their impact in clinical manifestations and complications of IBD. Finally, nutritional

therapy in IBD can be considered in two ways, as supportive and as primary treatment.

Supportive nutritional therapy aims to correct malnutrition and its metabolic consequences,

while nutritional primary therapy (in the form of enteral diet) may be effective in specific

subgroups of patients with Crohn’s disease, especially in children with poor nutritional status

or growth impairment.

Thiamin (B1), riboflavin (B2), niacin (nicotinic acid), pyridoxine (B6), pantothenic acid,

biotin, folic acid (B9) and vitamin B12 are referred to as members of the “vitamin B complex”.

These are water-soluble factors, playing an essential role in the metabolic processes of living

cells, functioning as coenzymes or as prosthetic groups bound to apoenzymes. These vitamins

are closely interrelated and impaired intake of one may impair the utilization of others.

Nutritional Issues in Inflammatory Bowel Disease… 59

This article focuses on the recent research for the aetiopathogenesis, the clinical

consequences and the management of the vitamin B complex deficiencies in patients with

inflammatory bowel disease.

1. Vitamin B Complex and the Aetiopathogenesis of IBD

The aetiopathogenesis of IBD is poorly understood. The role of genetic factors in IBD

pathogenesis is well established in previous studies and much progress has been achieved in

recent research to identify susceptibility genes for IBD. However, the geographic variation of

IBD incidence and the rising incidence of IBD in developed countries, while the genetic

background remained stable, indicates that environmental factors also play an important role

in IBD pathogenesis. The interaction between environmental factors (bacteria, viruses and

antigens) and predisposing genes results in chronic inflammatory process and tissue injury

mediated by the immune and non-immune cellular systems in the gut microenvironment

[1,2]. In addition, many epidemiological studies have revealed possibly important

associations between dietary factors and IBD, but there is still no conclusive evidence about

the role of specific dietary components in IBD pathogenesis [3]. Low fiber and fruit, high

sugar, high animal fat westernized diets have been proposed as risk factors for the

development of IBD [4].

There is limited data about of the role of “vitamin B complex” members in IBD

pathogenesis. In a recent study, Geerling et al. found that high intakes of vitamin B6 and fat

(mono- and polyunsaturated) may enhance the risk of developing ulcerative colitis [5]. The

authors could not explain the mechanisms responsible for the increased risk for UC with high

consumption of vitamin B6 and stated that they are uncertain whether this observation reflects

a true causal relationship or rather a certain dietary lifestyle in UC patients.

2. Malnutrition in IBD: Vitamin B Complex Deficiencies in IBD Patients

Malnutrition is a common feature in IBD patients with active disease, but is also

observed in patients with disease in remission. Nutrient deficiencies are more frequent in

Crohn’s disease of the small bowel compared to UC or Crohn’s disease limited to the colon.

Weight loss occurs in approximately 65-75% of CD patients [6] and 20-60% of UC patients

[6-9]. Besides weight loss, deficiencies in macronutrients and micronutrients may develop in

IBD patients during the disease course (Table 1). Patients with CD develop malnutrition

slowly and may present with multiple severe nutritional deficiencies, whereas patients with

UC are often well nourished, and develop acute nutritional deficiencies rapidly during acute

flare-ups of the disease [10].

Multiple factors are involved in the development of malnutrition and include poor dietary

intake, impaired nutrient digestion and absorption, increased nutrient requirements and

iatrogenic complications or drug effects (Table 2). In most patients, more than one factor is

responsible for the malnutrition. Decreased oral intake is one of the most important factors

for malnutrition development in IBD patients. The decreased intake can be due to a

60 Petros Zezos and Georgios Kouklakis

combination of anorexia, abdominal pain, nausea, vomiting, or dietary restrictions, either

iatrogenic or self-imposed. In Crohn’s disease, extensive inflammation or resection of the

small bowel is another important cause of malnutrition due to malabsorption. Moreover, in

CD patients bypassed loops of bowel, coloenteric fistulas and strictures may result in

bacterial overgrowth and malabsorption. Finally, drugs used in IBD patients may inhibit the

absorption of specific nutrients. Sulfasalazine decreases folate absorption and corticosteroids

inhibit calcium absorption.

Table 1. Prevalence of nutritional deficiencies in inflammatory bowel disease

 Prevalence (%)

Deficiency Crohn’s disease Ulcerative colitis

Weight loss 65-75 18-62

Hypoalbuminemia 25-80 25-50

Intestinal protein loss 75 R

Negative nitrogen balance 69 R

Anemia

 Iron deficiency

 Folic acid deficiency

 Vitamin B12 deficiency

25-85

39

67

48

66

81

30-40

5

Calcium deficiency 13 R

Magnesium deficiency 14-33 R

Potassium deficiency 5-20 R

Vitamin A deficiency 11 NR

Vitamin K deficiency R NR

Vitamin C deficiency R NR

Vitamin D deficiency 75 35

Zinc deficiency 50 R

Selenium deficiency 35-40 NR

R= reported but prevalence not described; NR= not reported

(Adapted from Dieleman LA, Heizer WD. Nutritional issues in inflammatory bowel disease.

Gastroenterol Clin North Am 1998;27:435-451 and Han PD, Burke A, Baldassano RN, Rombeau JL,

Lichtenstein GR. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am

1999;28:423-443)

Several vitamin deficiencies have been reported in IBD patients. With regard to watersoluble B vitamins, the vast majority of data refer to folate and B12, while there are a few

studies that have investigated the serum concentrations of thiamin (B1), riboflavin (B2),

niacin, biotin, pantothenic acid and pyridoxine (B6) in IBD patients.

Fernandes-Banares et al. evaluated the status of water-soluble and fat-soluble vitamins in

23 IBD patients with active disease and found that, among other nutrients, biotin, riboflavin,

folate, vitamin B1 and vitamin B12 serum levels were decreased in IBD patients compared to

89 healthy subjects. Although some patients had extremely low vitamin values, in no case

were clinical symptoms or syndromes due to the vitamin deficiency observed [11].

Nutritional Issues in Inflammatory Bowel Disease… 61

In another study, Kuroki et al. investigated the status of various vitamins in 24 patients

with Crohn’s disease. They found that vitamin B1, vitamin B2, and folate levels were

decreased in CD patients compared to control subjects. They also found that vitamin B2 and

niacin levels showed a negative correlation with disease severity [12].

Table 2. Causes of malnutrition in inflammatory bowel disease

1. Decreased nutrient intake

 Anorexia

 Altered taste

 Intake-associated pain or discomfort

 Iatrogenic dietary restrictions

2. Malabsorption

 Mucosal abnormalities

 Diminished absorptive surface

 Surgery

 Extensive disease

 Bacterial overgrowth

3. Excessive losses

 Protein-losing enteropathy

 Bleeding

 Fistula outputs

4. Increased requirements

 Hypercatabolic states

 Fever

 Sepsis

 Growth in children

5. Iatrogenic

 Surgical complications

 Drugs

 Corticosteroids

 Sulfasalazine

 Cholestyramine

 5-aminosalicylic acid

 Metronidazole

 Methotrexate

(Adapted from Graham TO, Kandil HM. Nutritional factors in inflammatory bowel disease.

Gastroenterol Clin North Am. 2002;31:203-18)

In addition, Geerling et al. assessed the nutritional status in 69 recently diagnosed IBD

patients and found that although nutritional intake of riboflavin was lower in UC patients

compared to controls, no significant difference in serum concentrations between the two

groups was noted, while serum concentration of vitamin B12 in CD patients was significantly

lower [13].

62 Petros Zezos and Georgios Kouklakis

Furthermore, Filippi et al. observed multiple nutritional deficiencies, including vitamin

B1, vitamin B6 and niacin, in patients with Crohn’s disease in remission [14]. On the contrary,

Geerling et al. although found significant low serum concentrations of several nutrients in

CD patients with disease in remission, they did not noticed deficiencies of the “vitamin B

complex” members [15].

Moreover, in a recent study Magee et al. analyzed the dietary intake of 81 UC patients

and found that endoscopic severity was positively related with the anti-thiamin additive

sulfite in food like white wine, burgers, sausages, lager and red wine [16]. Sulfite is a

precursor of sulfate that can potentially be reduced to sulfide by sulfate reducing bacteria in

the colon. Sulfide may a metabolic toxin in UC. Alternatively, the association of sulfite with

UC activity may be due to its ability to degrade thiamin, particularly in colonic pH,

promoting a metabolic disturbance to the gut microflora, since thiamin is a requirement for

the metabolism of the probiotic bacteria (lactobacilli).

Finally, Saibeni et al. investigated the vitamin B6 status in 61 IBD patients and found

that low vitamin B6 plasma levels, an independent risk factor for thrombosis, are frequent in

IBD patients, especially in those with active disease [17].

Folate and vitamin B12 nutritional status has been investigated more extensively in IBD

patients. Vitamin B12 deficiency is more frequently found in CD patients than UC patients

(Table 1). Although most vitamins and minerals are absorbed throughout the small intestine,

vitamin B12 is unique in that it is actively absorbed specifically in the terminal ileum [18].

Only a small amount is passively absorbed throughout the small bowel.

In patients with Crohn’s disease, besides decreased oral intake, resection or disease of the

terminal ileum can cause vitamin B12 malabsorption and deficiency. Many studies showed

impaired vitamin B12 absorption and decreased vitamin B12 serum levels in CD patients. Most

of them have studied the vitamin B12 absorption in operated CD patients, although there are

some studies that assessed the vitamin B12 status in patients with Crohn’s disease that have

not been operated.

Fernandes-Banares et al. [11] and Chowers et al. [19] found decreased vitamin B12 serum

levels in CD patients with small bowel or ileocecal disease and not in CD patients with

colitis. Geerling et al. [13] found that recently diagnosed CD patients had significantly lower

vitamin B12 levels compared to healthy controls, although other studies [12,20-22] did not

find any difference in vitamin B12 levels between CD patients and controls.

Ileal resection of more than 60 cm results in vitamin B12 malabsorption and decreased

vitamin B12 serum levels [23,24]. Behrend et al. [25] found that most Crohn’s disease patients

with ileal resection and ileorectal anastomosis had vitamin B12 malabsorption. Individuals

with more than 60 cm of ileal loss are particularly affected (100%), but approximately 50%

of patients with 10-60 cm ileal resection and 40% of patients with less than 10 cm ileal

resection also malabsorbed vitamin B12. On the contrary, in a recent study Duerksen et al.

investigated the vitamin B12 malabsorption in Crohn’s disease patients with limited ileal

resection and found that terminal ileal resections less than 20 cm were not at risk for vitamin

B12 deficiency [26]. Impaired vitamin B12 absorption after significant (more than 60 cm) ileal

resection may be permanent in adults, whereas in children adaptation of the remaining small

bowel may result in restoration of B12 absorption years after ileal resection [27].

Nutritional Issues in Inflammatory Bowel Disease… 63

Vitamin B12 deficiency is also known to occur in a small percentage of patients with

continent/pouch ileostomy [28,29]. In a series of 235 patients with IBD and continent

ileostomies, 27% of patients with CD were found to have subnormal or borderline

concentrations of vitamin B12 [30].

Kennedy et al. [31] observed that 12 CD patients with end ileostomies for at least 1 year

and variable lengths of ileal resection had lower vitamin B12 serum concentrations compared

to healthy controls. In a recent study, Jayaprakash et al. [32] stated that vitamin B12

deficiency in patients who have undergone end ileostomy is not very common, since it was

observed only in one patient out of 39 studied.

Ileal pouch–anal anastomosis (IPAA) has become the operation of choice for the surgical

management of ulcerative colitis (UC). Pouchitis is a potential complication in the ileal

pouch after restorative proctocolectomy. The etiology of pouchitis is unknown, but fecal

stasis and bacterial overgrowth play a major role in development of pouchitis. Anaerobic

organisms bind both vitamin B12 and the vitamin B12–intrinsic factor complex, and as a result

deficiency in vitamin B12 may be demonstrated in pouch patients [33]. Reduced vitamin B12

absorption (Schilling test) has been shown in 10–30% of patients with IPAA, and clinically

significant vitamin B12 deficiency has been documented in 3–9% of patients [29,34-36]. In a

recent study Kuisma et al. evaluated the long term metabolic consequences at least 5 years

after IPAA and the influence of pouchitis on pouch histology and on bile acid, lipid, and

vitamins B12, A, D and E metabolism, in 104 UC patients with a J-pouch [37]. Vitamin B12

malabsorption of ileal type was seen in 20% of patients with IPAA and vitamin B12

deficiency was observed in approximately 5% of IPAA patients.

 

[29] Selhub J, Jacques PF, Wilson PWF et al. Vitamin status and intake as primary

determinants of homocysteinaemia in an elderly population. JAMA 1993; 270:2693-8.

[30] Rimm EB, Willett WC, Hu FB et al. Folate and vitamin B6 from diet and supplements

in relation to risk of coronary heart disease among women. Ibid 1998; 279:359-64.

[31] Brouwer IA, van Dusseldorp M, Thomas CMG et al. Low-dose folic acid

supplementation decreases plasma homocysteine concentrations: a randomized trial.

Am J Clin Nutr 1999; 69:99-104.

[32] Malinow MR, Duell PB, Hess DL et al. Reduction of plasma homocysteine levels by

breakfast cereal fortified with folic acid in patients with coronary heart disease. New

Engl J Med 1998; 338:1009-15.

[33] Bronstrup A, Hages M, Prinz-Langenohl R et al. Effects of folic acid and combinations

of folic acid and vitamin B12 on plasma homocysteine concentrations in healthy young

women. Am J Clin Nutr 1998; 68:1104-10.

[34] Boushey CJ, Beresford SAA, Omenn GS et al. A quantitative assessment of plasma

homocysteine as a risk factor for vascular disease: probable benefits of increasing folic

acid intake. JAMA 1995; 274:1049-57.

[35] Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with

folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316:894-

8.

[36] Women's Health Initiative (WHI) Dietary Trial and Norwegian Vitamin Trial

(NORVIT). Prev Cardiol. 2006 Summer; 9(3):178-82.

[37] Bonaa KH, Njolstad I, Ueland PM et al. Homocysteine Lowering and Cardiovascular

Events after Acute Myocardial Infarction. N Engl J Med 2006 Apr 13; 354(15):1578-

88. Epub Mar 12

[38] Bottiglieri ET, Crellin RF, Reynolds EH. Folates and neuropsychiatry. In: Bailey L,

editor. Folate in health and disease. New York: Marcel Dekker, 1995; 435-62

Folic Acid and Health: An Overview 53

[39] Joosten E, Lesaffre E, Riezler R et al. Is metabolic evidence for vitamin B12 and folate

deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol

(series A) Biol Sci Med Sci 1997; 52:M76-9

[40] Clarke R, Smith AD, Jobst KA et al. Folate, vitamin B12 and serum homocysteine

levels in confirmed Alzheimer's disease. Arch Neurol 1998;11:1449-55

[41] Seshadri S, Beiser A, Selhub J et al. Plasma homocysteine as a risk factor for Dementia

and Alzheimer's disease’s. N. Engl. J. Med. 2002; 346: 476-483.

[42] Clarke R, Smith AD, Jobst, KA et al. Folate, Vitamin B12, and serum total

homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 1998; 55: 1449-

1455.

[43] Snowdon DA, Greiner LH, Mortimer JA et al. Serum folate and the severity of atrophy

of the neocortex in Alzheimer disease: findings from the NUN Study. Am. J. Clin. Nutr.

2000; 71: 993-998.

[44] Quinlivan EP, McPartlin J, Mcnulty H et al. Importance of both folic acid and vitamin

B12 in reduction of risk of vascular disease. Lancet 2002; 359: 227-228.

[45] Refsum H, Nurk E, Smith AD et al. The Hordaland Homocysteine Study (HHS): A

Community-Based Study of Homocysteine, Its Determinants and Associations with

Disease. J. Nutrition 2006, 136:1731S-1740S.

[46] Parnetti L, Bottiglieri T Lowenthal D. Role of Homocysteine in age-related vascualr

and non-vascular diseases. Aging. 1997, 9: 241-257.

[47] Bottiglieri T, Laundy M, Crellin R et al. Homocysteine, folate, methylation and

monoamine metbolism in depression. J Neurol Neurosurg Psychiatry 2000, 69; 228-

232

[48] Guttormsen AB, Ueland PM, Nesthus I et al. Determinants and vitamin responsiveness

of intermediate hyperhomocysteinemia. The HHS. J Clin Invest 1996, 98 (9) 2174-

2183

[49] Taylor MJ, Carney SM, Goodwin GM et al. Folate for depressive disorders: systematic

review and meta-analysis of randomized controlled trials. Journal of

Psychopharmacology 2004, 18 (2): 251-6.

[50] Eichholzer M, Luthy J, Moser U et al. Folate and risk of colorectal, breast and cervix

cancer: the epidemiological evidence. Swiss Med Wkly 2001; 131: 539-549.

[51] Jennings E. Folic acid as a cancer preventing agent. Medical Hypotheses 1995, 45 (3):

297-303.

[52] Cornel MC, Smit DJ and de Jong-van den Berg LT. Folic acid—the scientific debate as

a base for public health policy, Reprod Toxicol 2005, 20 pp. 411–415.

[53] Kim YI. Will mandatory folic acid fortification prevent or promote cancer?, Am J Clin

Nutr 2004, 80: pp. 1123–1128

[54] Kim YI. Role of folate in colon cancer development and progression, J Nutr 2003 133

(suppl 1), pp. 3731S–3739S.

[55] Charles D, Ness AR, Campbell D et al. Taking folate in pregnancy and risk of maternal

breast cancer, BMJ 2004, 329:pp. 1375–1376.

[56] Kotsopoulos J, Medline A and Renlund R et al., Effects of dietary folate on the

development and progression of mammary tumors in rats, Carcinogenesis 2005, 9:pp.

1603–1612

54 Rossana Salerno-Kennedy

[57] Giovannucci E, Rimm EB, Ascherio A et al. Alcohol, low methionine, low folate diets

and risk of colon cancer in men. J Natl Cancer Inst 1995;87:265-73

[58] Glynn SA, Albanes D, Pietinen P et al. Colorectal cancer and folate status: a nested

case-control study among male smokers. Cancer Epidemiol Biomarkers Prev 1996; 5:

487-94.

[59] Benito E, Stigglebout A, Bosch FX, Obrador A, Kaldor J, Mulet M et al. Nutritional

factors in colorectal cancer risk: a case-control study in Majorca. Int J Cancer

1991;49:161-7

[60] Meyer F, White E. Alcohol and nutrients in relation to colon cancer in middle-aged

adults. Am J Epidemiol 1993; 138: 225-36.

[61] Ferraroni M, La Vecchia C, D'Avanzo B, Negri E, Franceschi S, Decarli A. Selected

micronutrient intake and the role of colon cancer. Br J Cancer 1994; 70:1150-5.

[62] Freudenheim JL, Graham S, Marshall JR, Haughney BP, Cholewinski S, Wilkinson G.

Folate intake and carcinogenesis of the colon and rectum. Int J Epidemiol 1991;

20:368-74

[63] Giovannucci E, Stampfer MJ, Colditz GA et al. Multivitamin use, folate, and colon

cancer in women in the Nurses' Health Study. Annals of Internal Medicine 1998, 129

(7): 517-524

[64] Giovannucci E, Stampfer MJ, Colditz GA et al. Folate, methionine, and alcohol intake

and risk of colorectal adenoma. J Natl Cancer Inst. 1993 Jun 2; 85(11):875-84.

[65] KimY, Baik H, Fawaz K et al. Effects of folate supplementation on two provisional

molecular markers of colon cancer: a prospective, randomized trial. Am J Gastroenterol

2001; 96:184-95

[66] Ulvik A, Evenson E, Lien E et al. Smoking, folate and MTHRF reductase status as

interactive determinants of adenomatous and hyperplastic polyps of colorectum. Am J

Med Genet 2001:101:246-54

[67] Kim YI. Does a high folate intake increase the risk of breast cancer? Nutr Rev 2006

Oct; 64: 468-75

[68] Sellers TA, Kushi LH, Cerhan JR et al. Dietary folate intake, alcohol and risk of breast

cancer in a prospective study of postmenopausal women. Epidemiology 2001; 12

(4):420-8

[69] Sellers TA, Grabrick DM, Vierkant RA et al. Does folate intake decrease risk of

postmenopausal breast cancer among women with a family history? Cancer Causes

Control 2004 Mar; 15 (2): 113-20.

[70] Stolzenberg-Solomon RZ, Shih-Chen Chang, Leitzmann MF et al. Folate intake,

alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal

and Ovarian Cancer Screening Trial (PLCO). Am J Clin nutr 2006; 83:895-904.

[71] Larsson SC, Hakansson N, Giovannucci E et al. Folate intake and pancreatic cancer

incidence: a prospective study of Swedish women and men. J Natl Cancer Inst 2006

Mar 15; 98(6):407-13

[72] Larsson SC, Giovannucci E, Wolk A. Dietary folate intake and incidence of ovarian

cancer: the Swedish mammography Cohort. J Natl Cancer Inst 2004 Mar 3; 96(5):396-

402.

Folic Acid and Health: An Overview 55

[73] Campbell NR, How safe are folic acid supplements? Arch Intern Med 1996, 156: pp.

1638–1644.

[74] Eichholzer M, Tonz O, Zimmermann R. Folic acid: a public health challenge. Lancet

2006; 367: 1352-61

[75] Eichholzer M, Luthy J, Moser U et al. Safety aspects of folic acid for the general

population, Schweiz Rundsch Med Prax 2002, 91:pp. 7–16 [in German].

[76] Scott JM. Folate and vitamin B12. Proc Nutr Soc. 1999 May;58(2):441-8

[77] Food and Nutrition Board, Institute of Medicine (1998). Dietary reference intakes for

thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and

choline / a report of the Standing Committee on the Scientific Evaluation of Dietary

Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline and

Subcommittee on Upper Reference Levels of Nutrients. Washington, D.C.: National

Academy Press

[78] Kelly P, McPartlin J, Goggins M et al. Unmetabolised folic acid in serum: acute studies

in subjects consuming fortified foods and supplements. Am J Clin Nutr 1997; 65:1790-

5.

[79] JG Ray, LJ Langman, MM Mamdani and DE Cole, Absence of effect of folic acid flour

fortification on anticonvulsant drug levels, Am J Med (2005), 118 pp. 444–445

[80] Czeizel AE, Metneki J, Dudas I. The higher rate of multiple births after

periconceptional multivitamin supplementation: an analysis of causes, Acta Genet Med

Gemellol (Roma) 1994, 43 pp. 175–184.

[81] Ericson A, Källen B and Åberg A. Use of multivitamins and folic acid in early

pregnancy and multiple births in Sweden, Twin Res 2001, 4 pp. 63–66.

[82] Werler MM, Cragan JD, Wasserman CR et al. Multivitamin supplementation and

multiple births, Am J Med Genet 1997, 71 pp. 93–96.

[83] Martin JA and Park MM. Trends in twin and triplet births: 1980–97, Natl Vital Stat

Reps 1999, 47:pp. 1–16.

[84] Berry RJ, Kihlberg R and Devine O. Impact of misclassification of in vitro fertilisation

in studies of folic acid and twinning: modelling using population based Swedish vital

records, BMJ 2005, 330:pp. 815–818

[85] Vollset, HK Gjessing and A Tandberg et al. Folate supplementation and twin

pregnancies, Epidemiology 2005, 16: pp. 201–205

[86] Katz J, West KP Jr and Khatry SK et al., Twinning rates and survival of twins in rural

Nepal, Int J Epidemiol 2001, 30:pp. 802–807.

[87] Signore C, Mills JL, Cox C et al. Effects of folic acid fortification on twin gestation

rates, Obstet Gynecol 2005, 105:pp. 757–762.

[88] Waller DK, Tita AT and Annegers JF. Rates of twinning before and after fortification

of foods in the US with folic acid, Texas, 1996 to 1998, Paediatr Perinat Epidemiol

2003, 17pp. 378–383.

[89] Shaw GM, Carmichael SL, Nelson V et al. Food fortification with folic acid and

twinning among California infants, Am J Med Genet 2003, 119A pp. 137–140.

[90] Berry RJ, Li Z and Erickson JD et al., Prevention of neural-tube defects with folic acid

in China, N Engl J Med 1999, 341: pp. 1485–1490

[91] Kallen B. Reply to letter to the Editor, Early Hum Dev 2005, 81:pp. 469–470.

56 Rossana Salerno-Kennedy

[92] Munoz-Moran E, Dieguez-Lucena JL, Fernandez-Arcas N et al. Genetic selection and

folate intake during pregnancy, Lancet 1998, 352:pp. 1120–1121.

[93] Lucock M and Yates Z. Folic acid—vitamin and panacea or genetic time bomb? Nat

Rev Genet 2005, 6:pp. 235–240.

[94] Benchalal M, Yahchouchy-Chouillard E, Fouere S et al. Anaphylactic shock secondary

to intravenous administration of folinic acid: a first report, Ann Oncol 2002, 13: pp.

480–481

[95] Rubio IT, Cao Y, Hutchins LF, Westbrook KC, Klimberg VS. Effect of glutamine on

methotrexate efficacy and toxicity. Annals of Surgery 1998, 227 (5): 772-8.

[96] Wolff JE, Hauch H, Kuhl J, Egeler RM, Jurgens H. Dexamethasone increases

hepatotoxicity of MTX in children with brain tumors. Anticancer Research 1998, 18

(4B): 2895-9. .

[97] Kepka L, De Lassence A, Ribrag V et al. Successful rescue in a patient with high dose

methotrexate-induced nephrotoxicity and acute renal failure. Leukemia & Lymphoma

1998, 29 (1-2): 205-9. .

[98] Branda RF, Nigels E, Lafayette AR et al. Nutritional folate status influences the

efficacy and toxicity of chemotherapy in rats. Blood 1998, 92 (7): 2471-6.

[99] Shiroky JB. The use of folates concomitantly with low-dose pulse methotrexate.

Rheumatic Diseases Clinics of North America 1997, 23 (4): 969-80.

[100] Keshava C, Keshava N, Whong WZ et al. Inhibition of methotrexate-induced

chromosomal damage by folinic acid in V79 cells. Mutation Research 1998, 397 (2):

221-8.

[101] Morgan SL, Baggott JE. Folate antagonists in nonneoplastic disease: proposed

mechanisms of efficacy and toxicity". In Bailey LB, Folate in Health and Disease,

1995, 405-433. New York: Marcel Dekker. .

[102] Morgan SL, Baggott JE, Alarcon GS. Methotrexate in rheumatoid arthritis: folate

supplementation should always be given". BioDrugs 1997, 8 (1): 164-175

[103] Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents

deficient blood folate levels and hyperhomocysteinemia during longterm, low dose

methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease

prevention". Journal of Rheumatology 1998, 25 (3): 441-6.https://mawadealmaousoaa.blogspot.com/2023/02/vitamin-b-new-research.html